Graphene is continually being used to enhance real world applications. Archer Materials is progressing its work on its graphene-based biosensor technology.
The Australian company told shareholders on Thursday it has developed a new set of graphene materials that could be applied for enhanced biosensing and to aid in the development of biocompatible inks in water-based solvents.
Archer said doing so could eliminate the use of hazardous and non-biocompatible chemicals, increasing the scope of biomolecules that can be detected.
“There is no doubt that diseases have a devastating effect on economies and there is value in advancing disease diagnosis using simpler, more accurate biosensors,” Archer CEO Dr Mohammad Choucair said. “However, there are only a limited number of materials that can perform [biosensing], and they require innovative development.”
Archer said laboratory synthesis was complemented with computational chemistry to calculate and visualize the materials candidates at the atom-level for their suitability in biomolecular sensing.
“We have rapidly advanced from raw material feedstock to prototypes of a portable battery-powered sensing device that can incorporate biological material,” Choucair said. “This early stage work has the potential to allow much simpler and more effective sensing where early diagnosis of life-threatening diseases can lead to much improved outcomes.”
With Australia traditionally not so good at commercializing research and development, Archer touted its graphene-based biotechnology as at an early stage of commercialization.
It said it has been working with commercial advisors within the Australian biotech industry to produce a roadmap.
CEO of the National Graphene2D Association, John Weathersby, sees even more potential for graphene through this endeavor.
“Lasers have become commonplace across several industries and finding ways to consistently improve them benefits everyone,” Weathersby said.
Archer’s commercial strategy involves applying the “triple-helix business model” for biotechnology innovation to develop printable graphene-based biosensor componentry and sublicense the associated intellectual property rights.
It’s hoping to do this by developing commercial-grade prototypes; pursuing patent applications in Australia, the United States, and Europe; and establishing commercial partnerships.
Last month, Archer announced its plan to raise up to AU$3 million, offering shares at AU$0.60 per share. The funds raised will be used to increase the pace of Archer’s current work programs and to start hiring additional staff to do this work, it said.
Also, in May, Archer announced a new agreement with IBM which it hopes will advance quantum computing and progress work towards solutions for the greater adoption of the technology.
Joining the IBM Q Network, Archer will gain access to IBM’s quantum computing expertise and resources, seeing the Sydney-based company use IBM’s open-source software framework, Qiskit.
Source: ZD Net
The National Graphene2D Association (NGA2D) is the leading organization promoting the commercialization of graphene and graphene-like 2D materials in the United States. NGA2D members represent commercial graphene development, production, manufacturing and investment stakeholders as well as academic research institutions. For additional information visit www.nga2d.com